文献速递血管炎

血浆置换与糖皮质激素方案对ANCA相关性血管炎复发风险的随机对照试验

Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids.
PubMed 文献 · Arthritis Rheumatol · 2024-04-08

该研究是对一项国际双因素随机对照试验的事后分析,纳入704例重症ANCA相关性血管炎患者,比较血浆置换与无血浆置换、减少糖皮质激素暴露方案与标准方案对复发的影响。结果显示,649例(92.2%)达到缓解,147例(22.7%)共发生204次复发,复发率为每100患者年10.3次(95%CI 8.4-12.1);血浆置换和糖皮质激素方案均未显著改变复发风险。

要点

  • 重症ANCA相关性血管炎患者中复发仍常见,复发率为每100患者年10.3次(95%CI 8.4-12.1)。
  • 血浆置换与无血浆置换相比,复发风险无显著差异(亚风险比0.91-0.94,95%CI上限1.31)。
  • 减少糖皮质激素方案与标准方案相比,复发风险无显著差异(亚风险比0.93-0.94,95%CI上限1.35)。

核心结论

  • 在重症ANCA相关性血管炎患者中,复发仍然常见;血浆置换的使用或初始糖皮质激素减量方案均未影响复发风险。

研究设计与样本

  • 对一项国际双因素随机对照试验的事后分析,比较血浆置换与无血浆置换、减少糖皮质激素暴露方案与标准方案。
  • 纳入704例重症ANCA相关性血管炎参与者,采用三种竞争风险时间-事件模型估计治疗对任何严重程度复发的影响,并针对患者和疾病特征及其他治疗进行调整。

主要发现

  • 704例参与者中,649例(92.2%)达到缓解,147例(22.7%)发生204次复发。
  • 复发率为每100患者年10.3次(95%CI 8.4-12.1)。
  • 血浆置换的亚风险比为0.91-0.94(95%CI范围0.66至1.31),未显著改变复发风险。
  • 糖皮质激素方案的亚风险比为0.93-0.94(95%CI范围0.67至1.35),未显著改变复发风险。
  • 蛋白酶3-ANCA阳性及入组时存在非出血性呼吸系统表现与复发风险增加相关;基线时接受透析和口服环磷酰胺诱导治疗与复发风险降低相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Relapses of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are important events that can cause organ dysfunction and reduce quality of life. Understanding the effects of the initial treatments for ANCA-associated vasculitis on the subsequent risk of relapse may help guide monitoring and treatment. METHODS: We performed a post hoc analysis of participants with severe ANCA-associated vasculitis enrolled in an international two-by-two factorial randomized controlled trial comparing the effects of plasma exchange (PLEX) to no PLEX and a regimen of reduced glucocorticoid exposure to a standard regimen. We estimated the effects of treatments on relapses of any severity using three competing risk time-to-event models adjusted for patient and disease characteristics and other treatments. Each model was adjusted for disease manifestations in different ways. RESULTS: Of 704 participants, 649 (92.2%) achieved remission and 147 (22.7%) experienced 204 relapses. The relapse rate was 10.3 (95% confidence interval [CI] 8.4-12.1) relapses per 100 patient-years. Neither the use of PLEX (subhazard ratio 0.91-0.94; 95% CIs range from 0.66 to 1.31) nor a glucocorticoid regimen (subhazard ratio 0.93-0.94; 95% CIs range from 0.67 to 1.35) appreciably changed the risk of relapse. Proteinase 3-ANCA and the presence of nonhemorrhagic respiratory manifestations of the disease at trial entry were associated with increased risks of relapse. Receiving dialysis at baseline and administration of oral cyclophosphamide as induction therapy were associated with lower risks of relapse. CONCLUSION: In patients with severe ANCA-associated vasculitis, relapses remain common; neither the use of PLEX nor an initial glucocorticoid tapering regimen impacted relapse risk.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Junek ML, Merkel PA, Vilayur E, et al. Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids. Arthritis Rheumatol. 2024. PMID: 38485450. doi:10.1002/art.42843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。